| Identification | More | [Name]
AVP-AEW541 | [CAS]
475489-16-8 | [Synonyms]
AEW-541
AVP-AEW541
NVP-AEW541
NVP-AEW541(AEW541)
AVP-AEW541 NVP-AEW541
7-((1s,3s)-3-(azetidin-1-ylmethyl)cyclobutyl)-5-(3-(benzyloxy)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine
[7-[cis-3-[(Azetidin-1-yl)methyl]cyclobutyl]-5-(3-benzyloxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amine
7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[cis-3-(1-azetidinylmethyl)cyclobutyl]-5-[3-(phenylmethoxy)phenyl]-
[7-[cis-3-[(Azetidin-1-yl)methyl]cyclobutyl]-5-(3-benzyloxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amine AVP-AEW541 | [Molecular Formula]
C27H29N5O | [MDL Number]
MFCD22741515 | [MOL File]
475489-16-8.mol | [Molecular Weight]
439.552 |
| Chemical Properties | Back Directory | [Melting point ]
145℃ | [Boiling point ]
669.0±55.0 °C(Predicted) | [density ]
1.33 | [storage temp. ]
2-8°C | [solubility ]
Chloroform (Slightly), Methanol (Slightly) | [form ]
powder | [pka]
9.59±0.10(Predicted) | [color ]
white to beige | [InChIKey]
AECDBHGVIIRMOI-GRGXKFILSA-N | [SMILES]
C1=NC(N)=C2C(C3=CC=CC(OCC4=CC=CC=C4)=C3)=CN([C@@H]3C[C@H](CN4CCC4)C3)C2=N1 |
| Hazard Information | Back Directory | [Uses]
NVP-AEW541 is insulin-like growth factor I receptor (IGF-IR) inhibitor. | [Biological Activity]
nvp-aew541 is a novel, potent and selective inhibitor of igf-ir kinase with ic50 value of 0.086 μm [1].nvp-aew541 is a pyrrolo(2,3-d) pyrimidine derivative. it has been reported to abolish igf-i-induced igf-ir autophosphorylation and to block the igf-ir signaling pathway mainly in ecc-1 and uspc-1 cancer cells. also in these cell lines, nvp-aew541 has been shown to change the igf-i induced cell cycle and to lead apoptotic cell death as well as exhibit antiproliferative effects [2]. in addition, it is observed that nvp-aew541 can induce radiosensitization in pten wild-type cell lines [3]. | [Biochem/physiol Actions]
NVP-AEW541 is a reversible, ATP-competitive, orally available insulin-like growth factor-I receptor (IGF-IR, IGF-1R) inhibitor that, despite its equipotency against recombinant kinase domains of insulin receptor (InsR) and IGF-IR in cell-free kinase assays (IC50 = 140 & 150 nM, respectively), exhibits high selectivity toward cellular autophosphorylation of endogenous full-length IGF-1R (IC50 = 86 nM) over InsR (IC50 = 2.3 μM), HER1, PDGFR, c-Kit, and Bcr-Abl p210 (IC50 >5 μM). AEW541 effectively inhibits IGF-IR-mediated signaling and cancer survival (IC50 = 105 nM/MCF-7 soft agar growth, 1.64 μM/NWT-21 proliferation) in cultures and tumor growth in vivo (20 to 50 mg/kg twice daily p.o.; NWT-21 fibrosarcoma & TC-71 musculoskeletal sarcoma xenografts in mice). | [in vivo]
Oral administration of NVP-AEW541 (20, 30, or 50 mg/kg) results in abrogation of basal and IGF-I-induced receptor, and PKB and MAPK phosphorylation in the NWT-21 tumor xenograft[1]. NVP-AEW541 is administered by oral gavage [50 mg/kg in 0.2 mL of 25 mM L-(+)-tartaric acid] twice a day for 14 consecutive days. The control group is similarly treated with 0.2 mL carrier [25 mM L-(+)-tartaric acid] twice a day. Tumor volume and animal weight are measured thrice a week till the end of the treatment. At that time, animals are sacrificed and tumors are collected and formalin fixed for histologic and immunohistochemical analyses. In both cases, NVP-AEW541 treatment causes tumor shrinkage that reached the statistical significance (P=0.0156 and P=0.0111 for HTLA-230 and SK-N-BE2c, respectively)[2]. | [target]
IGF-IR kinase | [storage]
Store at -20°C | [References]
[1] carlos garc a-echeverr a, mark a. pearson, andreas marti, thomas meyer, juergen mestan, johann zimmermann, jiaping gao, josef brueggen, hans-georg capraro, robert cozens, dean b. evans, doriano fabbro, pascal furet, diana graus porta, janis liebetanz, georg martiny-baron, stephan ruetz, and francesco hofmann. in vivo antitumor activity of nvp-aew541—a novel, potent, and selective inhibitor of the igf-ir kinase. cancer cell.2004 mar (5):231-239.
[2] zohar attias-geva, itay bentov, ami fishman, haim werner, ilan bruchim. insulin-like growth factor-i receptor inhibition by speci c tyrosine kinase inhibitor nvp-aew541 in endometrioid and serous papillary endometrial cancer cell lines. gynecologic oncology. 2011 feb (121):383-389.
[3] sofie f. isebaert, johannes v. swinnen, william h. mcbride, and karin m. haustermans. insulin-like growth factor–type 1 receptor inhibitor nvp-aew541 enhances radiosensitivity of pten wild-type but not pten-deficient human prostate cancer cells. international journal of radiation oncology biology physics. 2011 (81):239-247. |
|
| Company Name: |
NCE Biomedical Co.,Ltd.
|
| Telephone: |
4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988 |
| Website: |
www.chemicalbook.com/ShowSupplierProductsList15748/0_EN.htm |
| Company Name: |
LETOPHARM LIMITED
|
| Telephone: |
+86-21-5821 5861 |
| Website: |
www.letopharm.com |
| Company Name: |
Sigma-Aldrich
|
| Telephone: |
021-61415566 800-8193336 |
| Website: |
https://www.sigmaaldrich.cn |
|